Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Srpt - The Untold Story

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta Therapeutics Inc. (NASDAQ:SRPT) shared topline data from the ESSENCE Phase 3 trial of Amondys 45 (casimersen) and Vyondys 53 (golodirsen) compared with placebo in 225 patients aged 6-13 years with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping.

What's Going On Sarepta Stock On Wednesday?

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc (NASDAQ:SRPT) highlight the delicate balance between innovation and patient safety in the biopharmaceutical industry.

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

inkl

Read news from The Economist, FT, and more,
with one subscription

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after the company issued an after-hours update on ongoing label expansion efforts for Elevidys, its approved gene therapy for Duchenne muscular dystrophy.

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market trading after the company announced it will engage in strategic restructuring and cost savings.

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures.

Top 3 Health Care Stocks That Could Blast Off In July

Top 3 Health Care Stocks That Could Blast Off In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next

Get all your
news in one place.

100's of premium titles.
One news app.

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC:RHHBY). Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after…

Where Sarepta Therapeutics Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to

Analyst Ratings For Sarepta Therapeutics

Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Sarepta Therapeutics

The European Medicines Agency

Roche Holdings AG

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

416,339 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play